IPO Year: 2015
Exchange: NASDAQ
Date | Price Target | Rating | Analyst |
---|---|---|---|
1/31/2025 | $26.00 | Mkt Outperform | JMP Securities |
7/29/2024 | $35.00 | Buy | TD Cowen |
3/28/2023 | $18.00 | Outperform | Evercore ISI |
9/29/2021 | $20.00 | Buy | Jefferies |
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock options to purchase 16,500 shares of Astria's common stock on February 3, 2025 under Astria's 2022 Inducement Stock Incentive Plan. The 2022 Inducement Stock Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of Astria. The options were granted as an inducement material to two employees entering into employment with Astria in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $7.43, which is equal to the closing price of Ast
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will participate in a fireside chat at the upcoming virtual Oppenheimer 35th Annual Healthcare Life Sciences Conference on Tuesday, February 11th at 10:40am ET. A webcast of the presentation can be accessed at the following link: https://wsw.com/webcast/oppenheimer39/atxs/2823424. An archived replay of the presentation will be available in the investors section of www.astriatx.com for 30 days following the event. About Astria Therapeutics: Astria Therapeutics is a bi
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present quality of life results from the Phase 1b/2 trial of navenibart (STAR-0215) in a poster displayed at the Western Society of Allergy, Asthma & Immunology (WSAAI) Annual Scientific Session in Waimea, Hawaii from Sunday, February 9 through Thursday, February 13, 2025. Dr. Marc A. Riedl, Professor of Medicine and Clinical Director of the U.S. HAEA Angioedema Center at the University of California, San Diego, will present quality of life data from the ALPHA-STAR trial of navenibart in an encore presentatio
-- Early Proof-of-Concept Results from the Phase 1a Trial Anticipated in Q3 2025 -- Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced initiation of a Phase 1a clinical trial of STAR-0310 in healthy subjects. STAR-0310, a high affinity monoclonal antibody OX40 antagonist that incorporates YTE technology, is in development for the potential treatment of atopic dermatitis (AD) and potentially other indications. The Phase 1a trial is intended to assess the safety, tolerability, pharmacokinetics, and immunogenicity of STAR-0310 in healthy adult participants. Astria expects ea
-- Single Pivotal Trial Designed to Demonstrate Efficacy and Safety of Every 3- and Every 6-Month Administration in a 6-Month Treatment Period -- -- Pioneering Patient-Centric Dosing Flexibility in HAE with Potential Market-Leading First-Choice Profile -- -- Phase 3 Initiation On-Track, Expected in Q1 2025 -- -- Strong Financial Position, Funded Through Expected Top-Line Phase 3 Results -- Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced its planned design of the ALPHA-ORBIT Phase 3 clinical trial of navenibart in people with hereditary angioedema (HAE), which wil
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock options to purchase 58,650 shares of Astria's common stock on January 2, 2025 under Astria's 2022 Inducement Stock Incentive Plan. The 2022 Inducement Stock Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of Astria. The options were granted as an inducement material to two employees entering into employment with Astria in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $8.97 which is equal to the closing price of Astri
-- Navenibart Demonstrated 6 Months of HAE Attack Prevention with 1 or 2 Doses -- -- 90-95% Mean Monthly Attack Rate Reduction Supporting Chronic Dosing 2 or 4 Times Per Year -- -- 67% Attack-Free Rate Over 6 Months in Cohorts 2 and 3 -- -- Favorable Safety and Well-Tolerated Profile -- -- Phase 3 Initiation on Track for Q1 2025 -- Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced positive final results from the target enrollment group of 16 patients in the ALPHA-STAR Phase 1b/2 clinical trial evaluating navenibart (STAR-0215), a monoclonal antibody inhibitor of
-- Phase 1a Trial of STAR-0310 in Healthy Volunteers Expected to Initiate in Q1 2025 -- -- Early Proof-of-Concept Results Expected in Q3 2025 -- Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced the U.S. Food and Drug Administration (FDA) clearance of its Investigational New Drug (IND) application for STAR-0310, a monoclonal antibody OX40 antagonist, the company is developing as a potential treatment for atopic dermatitis (AD) and potentially other indications. A Phase 1a trial of STAR-0310 in healthy subjects is expected to initiate in the first quarter of 2025, with
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock options to purchase 32,500 shares of Astria's common stock on December 2, 2024 under Astria's 2022 Inducement Stock Incentive Plan. The 2022 Inducement Stock Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of Astria. The options were granted as an inducement material to two employees entering into employment with Astria in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $10.37, which is equal to the closing price of As
-- Navenibart (STAR-0215), the Potential Market-Leading Therapy for the Treatment of Hereditary Angioedema, on Track for Expected Phase 3 Initiation in Q1 2025 -- -- Final 3- and 6-Month Results from the ALPHA-STAR Trial of Navenibart Expected in Q4 2024 -- -- STAR-0310 Investigational New Drug (IND) Application Submission On-Track for Year-End 2024 -- -- Phase 1a Trial of STAR-0310 in Healthy Subjects Expected to Initiate in Q1 2025 -- Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today reported financial results for the third quarter ended September 30, 2024, and provided a
4 - Astria Therapeutics, Inc. (0001454789) (Issuer)
4 - Astria Therapeutics, Inc. (0001454789) (Issuer)
4 - Astria Therapeutics, Inc. (0001454789) (Issuer)
4 - Astria Therapeutics, Inc. (0001454789) (Issuer)
4 - Astria Therapeutics, Inc. (0001454789) (Issuer)
4 - Astria Therapeutics, Inc. (0001454789) (Issuer)
4 - Astria Therapeutics, Inc. (0001454789) (Issuer)
4 - Astria Therapeutics, Inc. (0001454789) (Issuer)
3 - Astria Therapeutics, Inc. (0001454789) (Issuer)
4 - Astria Therapeutics, Inc. (0001454789) (Issuer)
4 - Astria Therapeutics, Inc. (0001454789) (Issuer)
4 - Astria Therapeutics, Inc. (0001454789) (Issuer)
4 - Astria Therapeutics, Inc. (0001454789) (Issuer)
JMP Securities initiated coverage of Astria Therapeutics with a rating of Mkt Outperform and set a new price target of $26.00
TD Cowen initiated coverage of Astria Therapeutics with a rating of Buy and set a new price target of $35.00
Evercore ISI initiated coverage of Astria Therapeutics with a rating of Outperform and set a new price target of $18.00
Jefferies initiated coverage of Astria Therapeutics with a rating of Buy and set a new price target of $20.00
SCHEDULE 13G/A - Astria Therapeutics, Inc. (0001454789) (Subject)
SCHEDULE 13G/A - Astria Therapeutics, Inc. (0001454789) (Subject)
SCHEDULE 13G/A - Astria Therapeutics, Inc. (0001454789) (Subject)
8-K - Astria Therapeutics, Inc. (0001454789) (Filer)
8-K - Astria Therapeutics, Inc. (0001454789) (Filer)
10-Q - Astria Therapeutics, Inc. (0001454789) (Filer)
S-8 - Astria Therapeutics, Inc. (0001454789) (Filer)
10-Q - Astria Therapeutics, Inc. (0001454789) (Filer)
8-K - Astria Therapeutics, Inc. (0001454789) (Filer)
10-Q - Astria Therapeutics, Inc. (0001454789) (Filer)
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced the appointment of Sunil Agarwal, M.D., to its Board of Directors. Dr. Agarwal has more than 20 years of biotechnology research, development, and commercialization experience. "It is a pleasure to welcome Sunil to our Board of Directors," said Jill C. Milne, Ph.D., Chief Executive Officer at Astria Therapeutics. "His extensive drug development and clinical expertise strongly complements our Board's skills and experiences, and we look forward to his contributions as we continue to advance our programs into later-stage cl
SC 13G/A - Astria Therapeutics, Inc. (0001454789) (Subject)
SC 13G/A - Astria Therapeutics, Inc. (0001454789) (Subject)
SC 13D/A - Astria Therapeutics, Inc. (0001454789) (Subject)
SC 13G/A - Astria Therapeutics, Inc. (0001454789) (Subject)
SC 13G - Astria Therapeutics, Inc. (0001454789) (Subject)
SC 13G/A - Astria Therapeutics, Inc. (0001454789) (Subject)
SC 13G/A - Astria Therapeutics, Inc. (0001454789) (Subject)
SC 13G/A - Astria Therapeutics, Inc. (0001454789) (Subject)
SC 13G/A - Astria Therapeutics, Inc. (0001454789) (Subject)
SC 13G/A - Astria Therapeutics, Inc. (0001454789) (Subject)
-- STAR-0215 Dosed Once or Twice Over 6 Months Reduced Monthly Attack Rates by 90-96%, Supporting Chronic Dosing 2 or 4 Times Per Year -- -- 92-100% Decrease in Moderate or Severe Attacks and 91-95% Reduction in Attacks Requiring Rescue Medications with STAR-0215 -- -- Very Well-Tolerated with No Serious Adverse Events and No Discontinuations -- -- Phase 3 Initiation on Track for Q1 2025, with Top-Line Results Expected by Year End 2026 -- -- Current Cash Expected to Fund Company into Mid-2027 -- -- Conference Call Today at 8:30am ET – Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, will report third quarter 2023 financial results before the Nasdaq Global Market open on Monday, November 13, 2023. Jill C. Milne, Ph.D., Chief Executive Officer, will host a conference call and webcast at 8:30am ET to provide an update on corporate developments and to discuss third quarter financial results. Webcast Information: Interested parties may join the webcast via the Investors section of the Astria website, www.astriatx.com, or with the following link: https://lifescievents.com/event/astria-2/. Please connect to the webca
-- Differentiated Preclinical Lead Candidate STAR-0310 to be Developed as a Potential Best-in-Class Long-Acting Treatment for Atopic Dermatitis – -- Conference Call and Webcast to be Held on October 12, 2023 at 8:30am ET -- Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it has entered into a worldwide exclusive license agreement with Ichnos Sciences for an OX40 portfolio to be developed for the potential treatment of atopic dermatitis (AD) and potentially for other allergic and immunological diseases. Astria plans to develop the lead candidate, called STAR-03
-- ALPHA-STAR Phase 1b/2 Trial in People with HAE Underway with Initial Proof-of-Concept Results Anticipated Mid-2024 -- -- Phase 1a Results Support STAR-0215's Target Profile as a Long-Acting Plasma Kallikrein Inhibitor with Estimated Half-Life of up to 117 Days -- -- Ended 4Q 2022 with Cash, Cash Equivalents, and Short-term Investments of $226M, Expected Cash Runway Through H1 2025 -- -- Webcast Today at 8:30am ET -- Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, today reported financial results for t
Astria Therapeutics, Inc. (NASDAQ:ATXS) a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, will report fourth quarter/full year 2022 financial results before the Nasdaq Global Market open on Wednesday, March 22, 2023. Jill C. Milne, Ph.D., Chief Executive Officer, will host a conference call and webcast at 8:30am ET to provide an update on corporate developments and to discuss fourth quarter and full year 2022 financial results. Webcast Information: Interested parties may join the webcast via the Investors section of the Astria website, www.astriatx.
-- Preliminary Results from Phase 1a Clinical Trial of STAR-0215 in Healthy Subjects Expected by Year-End 2022 -- -- Phase 1a Results Expected to Inform on STAR-0215's Profile to Prevent Attacks in Hereditary Angioedema -- Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, today reported financial results for the third quarter ended September 30, 2022 and provided a corporate update. "We are on track to report preliminary results from our Phase 1a trial of STAR-0215 by the end of this year. The trial is assessing safety and
-- FDA Cleared IND Application for STAR-0215 for the Treatment of Hereditary Angioedema -- -- Phase 1a Clinical Trial of STAR-0215 in Healthy Subjects Initiated, Preliminary Results Anticipated by Year-End 2022 -- -- Company to Host a Virtual R&D Day on September 30 -- Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, today reported financial results for the second quarter ended June 30, 2022, and provided a corporate update. "We are thrilled to announce that we have initiated dosing in our Phase 1a trial of STAR-0215 whic
-- On Track to File IND Application for STAR-0215 Mid-Year -- -- Initial Phase 1a Clinical Results Anticipated by Year End 2022 -- Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided a corporate update. "We are excited to advance STAR-0215 to the clinic this year with the planned initiation of our Phase 1a study," said Jill C. Milne, Ph.D., Chief Executive Officer of Astria. "STAR-0215 was created with a clear vision aim
-- STAR-0215, in Development to Treat HAE, on Track for Initial Phase 1 Clinical Results Expected by Year End 2022 -- -- New Preclinical Data on STAR-0215 Demonstrating High Potency and Extended Plasma Half-Life -- -- Findings on Burdens of Disease and Treatment in HAE Support Substantial Need to Decrease Patient Burden -- Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE), today reported financial results for the third quarter ended September 30, 2021 and provided a corporate update. "Our new company name, Astria, embodies our commitment to put patients first in all that we do. Astria originates fro
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE), will report third quarter 2021 financial results before the Nasdaq Global Market open on Wednesday, November 10, 2021. Jill C. Milne, Ph.D., Chief Executive Officer, will host a conference call and webcast at 8:30am ET to provide an update on corporate developments and to discuss third quarter financial results. Conference Call Dial-In Information: Participant Toll-Free Dial-In Number: (877) 388-2733 Participant International Dial-In Number: (541) 797-2984 Passcode: 3606309 Please specify to the operator that you